Table 1.

BoNT-A in CM treatment: issues to be addressed

Identification of responders	• Detailed sociodemographic and clinical characterization of patients
Improvement of clinical trial design	• Stratification of CM patients according to headache frequency • Use of restrictive efficacy endpoints • Assessment of synergistic effects of concomitant prophylaxis/treatments • Monitoring of concomitant evolution of modifiable CM risk factors
Understanding post-discontinuation relapse	• Exploring the usefulness of higher doses • Reconsidering BoNT-A mechanism of action

Abbreviations: BoNT-A, onabotulinum toxin A; CM, chronic migraine.